Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
- Positive Phase 3 Epidiolex pivotal trial in Lennox-Gastaut Syndrome (LGS) - - Positive FDA pre-NDA meeting - NDA for Dravet syndrome and LGS on track for H1 2017 submission -...
-
LONDON, Aug. 02, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing...
-
LONDON, July 18, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing...
-
LONDON, July 12, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH), (AIM:GWP), ("GW" or the “Company”), a biopharmaceutical company focused on discovering, developing and...
-
LONDON, July 12, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or the “Company”), a biopharmaceutical company focused on discovering, developing and...
-
- Primary endpoint achieved with high statistical significance (p=0.0135) showing that Epidiolex treatment reduces drop seizures compared to placebo - - Today’s LGS data follows successful Phase 3...
-
- Orphan Drug Designation Granted from FDA for Epidiolex for the Treatment of IS - - Phase 3 Trial Expected to Commence in Q4 2016 - LONDON, June 21, 2016 (GLOBE NEWSWIRE) -- GW...
-
LONDON, May 31, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing...
-
LONDON, May 16, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH), (AIM:GWP), (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing...
-
- Positive Phase 3 Epidiolex pivotal trial in Dravet syndrome -- Initial LGS Phase 3 pivotal data expected in June -- Conference call today at 9:00 a.m. EDT, 2:00 p.m. BST - LONDON, May 05, 2016 ...